|
Identification of new types of biomarkers and tracers for the in vivo molecular imaging of the pancreatic Beta-cell mass
Key Words: biomarkers, imaging, radiotracer, diabetes, pancreatic Beta-cell mass.
Consortium
- Companies: IBA (Coordinator), Eurogentec, Trasis
- Research centers: ULB (ULBD, ULBP, ULBI), UCL (Cellular Genetic & Molecular Imaging), ULg (Cyclotron Research Center), FUNDP (cellular biology)
Topic of the project
The goal of KeyMarker is to identify molecules that can be used as radiotracers for PET or SPECT imaging and potential quantification of the pancreatic Beta-cell mass. Such molecules may lead to novel approaches for diabetic disease management, such as patient stratification, disease follow-up and therapeutic options. Several ligands for the target will be screened and evaluated through the preclinical models developed for the project. The in vitro/in vivo preclinical platform as well as the toxicology, bio-distribution and labeling expertise dedicated to the project form the ground for a standard process for further diabetes imaging tracer evaluation.
Budget
This is a 3-year project with a total budget of M€ 2.7.
Contact
Richard Zimmermann (Coordinator of the project)
Email: richard.zimmermann@iba-group.com
IBA
Website: http://www.group.iba-worldwide.com
|
|
|
|